
Please try another search
(Reuters) -U.S. health regulators are expected to authorize a booster shot of Pfizer/BioNTech's COVID-19 vaccine for children aged 5 to 11 as soon as Tuesday, the New York Times reported on Monday, citing people familiar with the matter.
The companies submitted an application to the U.S. Food and Drug Administration for the authorization last month.
They have cited data from a mid- to late-stage study showing a third dose of their shot increased protection against the original coronavirus version and the Omicron variant among children in the age group.
It is unclear how much demand there is for the third dose in the age group. Just 28.8% of children aged 5 to 11 are fully vaccinated, according to data from the U.S. Centers for Disease Control and Prevention.
A meeting of outside vaccine experts on an advisory committee to the Centers for Disease Control and Prevention has been scheduled for Thursday, the report https://www.nytimes.com/2022/05/16/us/politics/fda-pfizer-booster-children.html?searchResultPosition=1 said.
The FDA declined to comment, while Pfizer (NYSE:PFE) and BioNTech did not respond to requests for comment.
Investing.com – Germany stocks were lower after the close on Monday, as losses in the Retail, Construction and Technology sectors led shares lower. At the close in Frankfurt, the...
Investing.com – France stocks were higher after the close on Monday, as gains in the Utilities, Healthcare and Industrials sectors led shares higher. At the close in Paris, the...
By Markus Wacket BERLIN (Reuters) - The German government will be able to buy stakes in energy companies buckling under the cost of soaring gas import prices, according to draft...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.